Low Leverage / Clean Balance SheetA debt-free capital structure and a materially larger equity base improve solvency and lower financial risk over months. This durable strength reduces interest obligations and gives management flexibility to fund R&D or seek partnerships without immediate refinancing pressure, supporting runway.

Revenue Rebound In 2025A positive revenue inflection, even from a small base, signals nascent commercial traction or milestone receipts. If sustained, this trend can validate the development pathway, provide non-dilutive funding sources, and improve credibility with partners and investors over the medium term.

Lean Operating FootprintA very small headcount implies low fixed overhead and a capital-light operating model typical for early-stage biotechs. This reduces baseline cash burn, extending runway from existing resources and allowing focused spending on core TRPV1 development without large personnel-driven expense commitments.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow indicates the company consumes cash steadily and will need external financing absent material revenue or partnership deals. Ongoing burn strains runway, risks dilution or costly financing, and limits ability to scale programs without funding events.

Widening Net LossesGrowing net losses reflect that R&D and operating expenses are accelerating faster than revenue gains. This persistent deficit erodes equity and heightens the need for capital raises; without demonstrable clinical or commercial milestones, losses will pressure long-term financial viability.

Small, Volatile Revenue BaseA tiny and inconsistent revenue stream leaves the business dependent on financing or licensing to fund development. Lack of recurring, diversified revenue reduces resilience to setbacks, makes margins unsustainable at current scale, and increases long-term execution risk until commercialization.

PILA FAQ

What was PILA PHARMA AB’s price range in the past 12 months?

PILA PHARMA AB lowest stock price was kr1.02 and its highest was kr3.93 in the past 12 months.

What is PILA PHARMA AB’s market cap?

PILA PHARMA AB’s market cap is kr51.85M.

When is PILA PHARMA AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PILA PHARMA AB’s earnings last quarter?

Currently, no data Available

Is PILA PHARMA AB overvalued?

According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PILA PHARMA AB pay dividends?

PILA PHARMA AB does not currently pay dividends.

What is PILA PHARMA AB’s EPS estimate?

PILA PHARMA AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PILA PHARMA AB have?

PILA PHARMA AB has 42,084,415 shares outstanding.

What happened to PILA PHARMA AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of PILA PHARMA AB?

Currently, no hedge funds are holding shares in SE:PILA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PILA PHARMA AB

PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2a clinical trials for type 2 diabetes. PILA PHARMA AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.